title: Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.
abstract: Aspartylglycosaminuria (AGU) is a lysosomal storage disease caused by deficient activity of glycosylasparaginase (AGA), and characterized by motor and mental retardation. Enzyme replacement therapy (ERT) in adult AGU mice with AGA removes the accumulating substance aspartylglucosamine from and reverses pathology in many somatic tissues, but has only limited efficacy in the brain tissue of the animals. In the current work, ERT of AGU mice was initiated at the age of 1 week with three different dosage schedules of recombinant glycosylasparaginase. The animals received either 3.4 U of AGA/kg every second day for 2 weeks (Group 1), 1.7 U/kg every second day for 9 days followed by an enzyme injection once a week for 4 weeks (Group 2) or 17 U/kg at the age of 7 and 9 days (Group 3). In the Group 1 and Group 3 mice, ERT reduced the amount of aspartylglucosamine by 34 and 41% in the brain tissue, respectively. No therapeutic effect was observed in the brain tissue of Group 2 mice. As in the case of adult AGU mice, the AGA therapy was much more effective in the somatic tissues than in the brain tissue of the newborn AGU mice. The combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease.
authors.affiliation: Eastern Finland Laboratory Centre, Kuopio, Finland.
authors.forename: Ulla
authors.initials: U
authors.lastname: Dunder
authors.forename: Pirjo
authors.initials: P
authors.lastname: Valtonen
authors.forename: Eira
authors.initials: E
authors.lastname: Kelo
authors.forename: Ilkka
authors.initials: I
authors.lastname: Mononen
mesh_terms: D000117:Acetylglucosamine / Q000031:analogs & derivatives / Q000652:urine; D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D054880:Aspartylglucosaminuria / Q000201:enzymology / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D001227:Aspartylglucosylaminase / Q000008:administration & dosage* / Q000235:genetics; D015415:Biomarkers / Q000652:urine; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D056947:Enzyme Replacement Therapy; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D018345:Mice, Knockout; D041681:NIH 3T3 Cells; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D014162:Transfection
chemical_list: D015415:Biomarkers; D011994:Recombinant Proteins; C000009:N-acetylglucosaminylasparagine; D001227:Aspartylglucosylaminase; D000117:Acetylglucosamine